StreetAlpha.app
Home › Stocks › VRTX

Vertex Pharmaceuticals Inc / MA (VRTX)

Healthcare
$534.20
▼ −0.67%
LAST CLOSE · NOV 17

Vertex Pharmaceuticals develops and sells prescription medicines for cystic fibrosis, blood disorders, acute pain and serious kidney diseases. It last closed at $534.20 on Nov 17, down 0.67% on the day. VRTX reports earnings on Thu, Feb 11, 2027. The average 12-month price target from 11 analysts is $626.18 (+17.2% from the last close), with a high of $725.00 and a low of $563.00. Analyst consensus is Strong Buy, based on the latest ratings from 11 firms (10 buy, 1 hold, 0 sell). Over the past 90 days StreetAlpha recorded 4 whale options trades in VRTX, 50% of them bullish and 50% bearish. In the past 30 days there were 13 dark pool prints totaling $27.7M, the largest $16.3M.

AI Auto Pilots
Is VRTX in one of our four AI portfolios? Sign in free to see

Key Stats

Last 12 months
Results
Revenue
$13.0B
+10.5% vs a year ago
Net income
$4.0B
+8.2% vs a year ago
EPS (diluted)
$15.54
+9.4% vs a year ago
Free cash flow
$3.2B
24.7% margin
Valuation
Market cap
$135B
253.5M shares
P/E
34.4
Price over 12 month EPS
Price to sales
10.5
Market cap over revenue
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$5.0B
At Sep 30
Debt
$4.5B
At Sep 30
Shareholder equity
$20.9B
Buybacks
$1.1B
Last 12 months
CEOReshma Kewalramani
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: $7.6B$7.6BFY2021FY2022: $8.9B$8.9BFY2022FY2023: $9.9B$9.9BFY2023FY2024: $11.0B$11.0BFY2024FY2025: $12.0B$12.0BFY2025

From VRTX's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 3). Last 12 months adds up the four latest quarters.

Next report
Feb 11
2027 · Time not announced
Consensus EPS forecast
$4.20
$3.50B revenue est.
Year-ago EPS
—
Not on file
Options-implied move
—
Posted about a week before
Analyst consensus
Strong Buy
Based on 11 analyst ratings (90 days)
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Consensus · 90 days
Strong Buy
11firms
10 Buy1 Hold0 Sell
Each firm's latest rating on VRTX in the past 90 days
Average 12-month target
$626.18
▲ 17.2% upside

Based on 11 analysts who set a price target on VRTX in the past 90 days. The average target is $626.18, with a high of $725.00 and a low of $563.00, compared with the last close of $534.20.

Low $563.00Avg $626.18High $725.00
Blue marker: last close $534.20
Highest target$725.00
Average target$626.18
Lowest target$563.00
Latest rating changes
BarclaysTarget raised
Nov 4Buy$617 → $626
JP MorganTarget raised
Nov 3Buy$560 → $570
Goldman SachsMaintained
Nov 3Buy$725
Morgan StanleyTarget lowered
Nov 3Buy$665 → $660
ScotiabankMaintained
Nov 3Buy$660
DateFirmActionRatingPrice target
Nov 4BarclaysTarget raisedBuy$617 → $626
Nov 3JP MorganTarget raisedBuy$560 → $570
Nov 3Goldman SachsMaintainedBuy$725
Nov 3Morgan StanleyTarget loweredBuy$665 → $660
Nov 3ScotiabankMaintainedBuy$660
Loading…

Technical Analysis

VRTX · as of the Nov 17 close · updated after every close
Uptrend

The stock sits between its 20 and 50 day averages. It is 9% above its 200 day average, so the longer trend is still up. Momentum is fading (RSI 50). The nearest support is the Pivot at $533.92, and the nearest resistance the swing high (Oct 22) at $537.81.

Short trendBullish
Long trendBullish
MomentumFading
StretchNormal
VolatilityHigh, 2.8%/day
Key levels
$568.6752 week high+6.5%
$538.84Pivot R1+0.9%
$538.6120 day average+0.8%
$537.81Swing high (Oct 22)+0.7%
$534.20Last close
$533.92Pivot−0.1%
$532.23Swing low (Aug 31)−0.4%
$529.28Pivot S1−0.9%
$522.3150 day average−2.2%
$515.91100 day average−3.4%
$483.99200 day average−9.4%
$412.2752 week low−22.8%
Indicators
RSI (14)50.38Middle of its rangeNeutral
MACD5.78Below its signal lineBearish
Stochastic36.7Middle of its rangeNeutral
ADX (14)12.2No clear trend
Williams %R-83.5Oversold below −80, overbought above −20Oversold
CCI (20)-31.5Oversold below −100, overbought above 100Neutral
Rate of change+0.7%Change over 10 sessionsBullish
ATR (14)$15.06Typical daily range, 2.8% of price
MA 10Below
MA 20Below
MA 50Above
MA 100Above
MA 200Above
What happened before, for VRTX

What happened before

See how VRTX did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

Whale flow is mixed2 bullish and 2 bearish whale options trades in the last 90 days. See Whale Flow
November seasonalityHow VRTX usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Seasonality

How VRTX has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2006.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D
Total alerts
4
Bullish
2
50%
Bearish
2
50%
Date span
Aug 21 – Oct 26
Loading…

See today’s whale options flow across the market →

Dark Pool

30D
Prints
13
Notional
$27.7M
Largest print
$16.3M
Loading…

VRTX Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Neutral
Strongly bearishNeutralStrongly bullish
  • ▲914 buying vs 682 selling
  • ▼Held by funds -1.8 pts
  • ▲Funds holding +22
  • ▲Superinvestors: 4 added, 1 cut
  • ▼Put/call 1.42 to 2.32
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding1,7861,764+1.2%
In funds' top 101912+58.3%
Held by funds94.2%96.0%−1.8 pts
New / increased149 / 765175 / 704+4.0%
Reduced / sold out574 / 108615 / 111−6.1%
Put/call ratio2.321.42+63.3%
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See VRTX institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

VRTX Stock Buybacks

See all S&P 500 buybacks →
Spent, 12 months
$1.1B
0.8% yield
Left in program
$2.5B
1.8% of value
Shares outstanding, 12 months
−0.1%
Fewer shares
Last quarter
$121.8M
Sep 2026
Avg price paid, last quarter
$486.15
251K shares bought
S&P 500 rank by spending
#178 of 358
 
Spent each quarter, last 3 yearsTop bar $1.1B
Dec 2023: $143.5M, average price $360.62Mar 2024: $140.4M, average price $418.20Jun 2024: $315.8M, average price $429.06Sep 2024: $307.6M, average price $480.60Dec 2024: $427.4M, average price $444.63Mar 2025: $416.9M, average price $447.03Jun 2025: $394.5M, average price $454.12Sep 2025: $1.1B, average price $397.10Dec 2025: $105.1M, average price $409.11Mar 2026: $344.5M, average price $464.79Jun 2026: $455.0M, average price $440.17Sep 2026: $121.8M, average price $486.15
Dec 2023Sep 2026
For membersMonth by month buying, shares and the average price paid each month are shown to AI Starter and AI Pro members.

From the company's 10-Q filed Nov 3, 2026. Quarters are the company's own fiscal quarters. Yield and % of value use the latest close. Buybacks are not a forecast: in our testing, the biggest buyers did about the same as the average S&P 500 stock.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether VRTX is in one of them and how their past VRTX trades turned out.

VRTX in the AI portfolios
Loading…

VRTX News Tone and Price

Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered VRTX in an article yet. Here's the latest on the wider market.

VRTX Congress Trades

All congress trades →
Trades, 12 months
20
Buys
11
55%
Sells
9
45%
People
6
Last filed Nov 5
Who traded VRTX · since 2017
Latest 5 filings of 86
$1K – $15KTraded Oct 7, 2026Filed Nov 5, 2026
$1K – $15KTraded Sep 4, 2026Filed Oct 7, 2026
$15K – $50KTraded Jul 23, 2026Filed Sep 22, 2026
$1K – $15KTraded Aug 26, 2026Filed Sep 7, 2026
$1K – $15KTraded Mar 27, 2026Filed Jul 21, 2026
PersonTypeAmountTradedFiledDelay
Ro KhannaD · CASell$1K – $15KOct 7, 2026Nov 5, 202629 d
Ro KhannaD · CABuy$1K – $15KSep 4, 2026Oct 7, 202633 d
Donald J TrumpExecutive branchBuy$15K – $50KJul 23, 2026Sep 22, 202661 d
David TaylorR · OHSell$1K – $15KAug 26, 2026Sep 7, 202612 d
Alan ArmstrongHouseBuy$1K – $15KMar 27, 2026Jul 21, 2026116 d

Members of Congress and senior officials report trades up to 45 days later, as dollar ranges. Filings show a trade happened, not why. Not investment advice.

About Vertex Pharmaceuticals Inc / MA

Vertex Pharmaceuticals is a biotechnology company based in Boston, Massachusetts, that develops and sells prescription medicines for serious diseases. Its approved products treat cystic fibrosis, sickle cell disease and beta thalassemia, and acute pain. The company also has clinical programs for kidney diseases, diabetic nerve pain and type 1 diabetes. Its customers include patients, healthcare providers, and insurers and payors that cover its treatments.

Headquarters
Boston, MA
Founded
1989